Ustekinumab for the treatment of psoriatic arthritis: an update
نویسندگان
چکیده
Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.
منابع مشابه
Update on treatment of psoriatic arthritis.
Some of this past year's key papers or abstracts on psoriatic arthritis (PsA) assessment and treatment are reviewed in this paper. Treatment begins with identification of the PsA patient. Several screening questionnaires have been developed to be used in dermatology and primary care settings to identify which patients with psoriasis have developed PsA as opposed to other common musculoskeletal ...
متن کاملEarly psoriatic arthritis: should we treat it in the same way as we treat rheumatoid arthritis?
2015 Joint damage predicts functional limitation and mortality in psoriatic arthritis patients, but evidence from cohort studies supports the idea that early diagnosis and treatment are beneficial. Given the revolution in the treatment of rheumatoid arthritis, treating to targets and close control have become attractive concepts in the clinical management of psoriatic arthritis. The evidence in...
متن کاملComparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab
The development of psoriasis and psoriatic arthritis is a multistep process that leads to chronic or recurrent inflammation. Recent studies have suggested the importance of T helper (TH)1 and TH17 cells, accessory cells, and proinflammatory cytokines in the pathogenesis of the enthesis, synovium, and skin involvement in psoriasis in the presence of susceptibility genes that remain quiescent unt...
متن کاملPharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.
OBJECTIVE To update the evidence on the efficacy and safety of pharmacological agents in psoriatic arthritis (PsA). METHODS Systematic literature review of randomised controlled trials comparing pharmacological interventions in PsA: non-steroidal anti-inflammatory drugs, glucocorticoid, synthetic disease modifying antirheumatic drugs (sDMARDs) either conventional or targeted, biologicals (bDM...
متن کاملUstekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement
Ustekinumab is a fully human monoclonal antibody targeting the common p40 subunit shared by interleukin (IL)-12 and IL-23. Ustekinumab prevents the interaction of IL-12 and IL-23 with their cell surface receptors, and thus blocks T helper (Th)-1 IL-12 and Th-17 IL-23 inflammatory pathways. Ustekinumab has been evaluated in the treatment of various chronic immune-mediated diseases including, pso...
متن کامل